The London Stock Exchange uses cookies to improve its website. The cookies for analytical purposes have already been set. For more details and how to manage cookies, please see our privacy and cookies policy.

Welcome stories


31 March 2005
31/03/2005 Proximagen Neuroscience opens the market

31 March 2005

 

Proximagen Neuroscience plc opens the market

 

 

Proximagen Neuroscience plc, the drug discovery and development company that is focused on neurodegenerative disease, was founded in November 2003 by Professor Peter Jenner, in conjunction with King’s College London, to draw upon over 25 years of pre-eminent neurodegenerative research.

 

Proximagen’s business strategy is focused on the identification, development and subsequent commercialisation of novel therapeutics to improve the quality of life and address the medical needs for patients suffering from neurodegenerative disease such as Parkinson’s disease and Alzheimer’s disease. 

 

£13.5m (£12.6m net of expenses) was raised for Proximagen via a Placing at 148p per share.  On admission the market capitalisation of Proximagen at the Placing Price was £29.7m.  The proceeds of the Placing will be used to finance the Company’s drug development programmes in Parkinson’s disease and Alzheimer’s disease.  KBC Peel Hunt Ltd was the Company’s nominated adviser and broker.

 

Commenting on the flotation, Kenneth Mulvany, Proximagen’s Chief Executive Officer, said: “I am delighted with the response to Proximagen’s flotation.  Commencing life as a public company is extremely exciting for us and we look forward to progressing our drug development programmes in Parkinson’s disease and Alzheimer’s disease and to generating value for our shareholders.”

.

The Exchange accepts no responsibility for the content of the website you are now accessing or for any reliance placed by you or any person on the information contained on it.

By allowing this link the Exchange does not intend in any country, directly or indirectly, to solicit business or offer any securities to any person.

You will be redirected in five seconds.

You are accessing the London Stock Exchange Annual Report Service powered by PrecisionIR.

The Exchange accepts no responsibility for the content of the reports you are now accessing or for any reliance placed by you or any person on the information contained therein.

By allowing this link the Exchange does not intend in any country, directly or indirectly, to solicit business or offer any securities to any person.

You will be redirected in five seconds